$AVR

L1 Capital Pty Ltd sold $187K of AVR (indirect holdings)

L1 Capital Pty Ltd sold 23,000 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at $8.13 ($0.19M total) on 2026-07-24.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Jul 28, 2026, 12:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 1:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

The newest concrete fact is the reported open-market sale size, price, and post-transaction share count, which may influence short-term sentiment but does not introduce new operating or regulatory information.

02

Market read

Traders may monitor for follow-on insider activity or changes in ownership, but the filing alone is unlikely to drive a durable repricing without additional catalysts.

03

What to watch

The article does not provide context for why the sale occurred (taxes, diversification, estate planning) and does not include any concurrent buy/sell by other insiders or changes in company outlook.

Relevance 4/10Novelty 4/10Timing: after-hours filing timestamp on 2026-07-28 for a 2026-07-24 sale

Background

This is an SEC Form 4 insider transaction disclosure for Anteris Technologies Global Corp. (AVR), reported by L1 Capital Pty Ltd as a 10% owner via indirect holdings.

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

L1 Capital Pty Ltd, a 10% owner, filed a Form 4 showing an indirect open-market sale of 23,000 shares at $8.13 on 2026-07-24.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

Form 4 provides transaction details (size, price, post-sale holdings) but the article includes no new company-specific catalyst, and it states no 10b5-1 plan.

Market effects

No sector read-across; this is a single issuer insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity management by a large holder, especially since the filing is for an indirect position and does not cite any company-specific issue.

Key entities

  • Anteris Technologies Global Corp.

    Subject of the Form 4 insider transaction disclosure (ticker AVR).

  • L1 Capital Pty Ltd

    Reporter of the Form 4, selling 23,000 shares indirectly at $8.13 on 2026-07-24.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

$AVRLow

Anteris Technologies Global Corp. (AVR): Results of Operations and Financial Condition

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe

$AVRMed

Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global (NASDAQ:AVR) shares rose 12.6% to $10.0750 on Thursday, after closing at $8.95; the stock traded between $9.71 and $10.0750. Volume was 176,960 shares, down 84% vs. average. Analysts cited mixed views: Barclays raised its target to $18 (overweight), while Wall Street Zen moved to hold; consensus target is $16. In its May 12 earnings, the company reported -$0.28 EPS vs -$0.27 expected on $0.49M revenue vs $0.77M.